Y-Intercept (HK)’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.64M Sell
14,293
-8,630
-38% -$1.88M 0.06% 486
2026
Q2
$5.61M Buy
+22,923
New +$4.97M 0.11% 247
2026
Q1
– Sell
-34,854
Closed -$6.37M – 1552
2025
Q4
$6.37M Buy
34,854
+7,827
+29% +$1.09M 0.14% 154
2025
Q3
$3.28M Sell
27,027
-3,613
-12% -$407K 0.08% 364
2025
Q2
$3.2M Buy
30,640
+17,895
+140% +$1.89M 0.08% 388
2025
Q1
$1.49M Buy
+12,745
New +$1.45M 0.1% 263
2024
Q4
– Sell
-7,958
Closed -$715K – 1180
2024
Q3
$715K Sell
7,958
-3,617
-31% -$316K 0.04% 598
2024
Q2
$932K Buy
+11,575
New +$857K 0.05% 519
2024
Q1
– Sell
-11,285
Closed -$898K – 1363
2023
Q4
$898K Buy
+11,285
New +$754K 0.08% 353
2022
Q3
– Sell
-7,715
Closed -$295K – 960
2022
Q2
$295K Buy
7,715
+941
+14% +$29.8K 0.04% 590
2022
Q1
$280K Buy
+6,774
New +$210K 0.06% 475
2021
Q3
– Sell
-3,634
Closed -$245K – 643
2021
Q2
$245K Buy
+3,634
New +$218K 0.06% 476
2021
Q1
– Sell
-6,637
Closed -$553K – 620
2020
Q4
$553K Buy
+6,637
New +$496K 0.23% 128

Other funds holding AXSM

Y-Intercept (HK)'s AXSM Position: Q3 2026 in Review

Y-Intercept (HK) reduced its Axsome Therapeutics (AXSM) stake by 38% in Q3 2026, selling an estimated $1.88M and leaving 14,293 shares worth $2.64M. The position accounts for 0.06% of the portfolio, ranked #486.

Y-Intercept (HK) first reported a position in AXSM in Q4 2020 and has held it in 13 quarters since. The position peaked at $6.37M in Q4 2025. 49 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Y-Intercept (HK) held 14,293 shares of Axsome Therapeutics worth $2.64M as of Q3 2026.
  • Y-Intercept (HK) sold 8,630 Axsome Therapeutics shares in Q3 2026, an estimated $1.88M.
  • Axsome Therapeutics made up 0.06% of Y-Intercept (HK)'s portfolio in Q3 2026, its #486 holding.
  • Y-Intercept (HK) first reported a position in Axsome Therapeutics in Q4 2020 and has held it in 13 quarters since.
  • Y-Intercept (HK)'s Axsome Therapeutics position peaked at $6.37M in Q4 2025.
  • 49 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.